| Name | Title | Contact Details |
|---|
Genetic Technologies, Inc. is an independent, full service and multi-accredited DNA forensic science company focusing primarily on the testing and evaluation of forensic evidence as it relates to human identification. Established in 1998, Genetic Technologies, Inc. serves a rapidly growing nationwide and worldwide customer base of private citizens, investigators, law enforcement agencies, public defenders, criminal defense attorneys, and prosecutors. We offer our clients access to a broad range of forensic biology technologies—specializing in DNA analysis, (Autosomal and Y-STRs), touch DNA (Low Copy Analysis), Crime Scene Investigation (CSI), serology, and expert witness & consulting services for civil investigations / criminal prosecution & defense. Our forensic division has played a pivotal role in a hundreds of high profile criminal cases with our civil and relatedness divisions assisting clients in thousands of immigration / relatedness DNA tests including a wide spectrum of infidelity scenarios. Our seasoned staff of expert scientists utilizes the most advanced methodologies available to detect and test DNA from many sources. We offer fast, accurate and personalized service for each of our customers, including consulting and expert witness services in conjunction with forensic testing. Genetic Technologies, Inc. is a leader in the Forensic Science and Human Identification Industry and provides specialized software to the eDNA Consortium. eDNA is a software developed by Genetic Technologies, Inc. which is used by many facilities in the Human Identification Industry.
beBright is a pediatric dentistry and orthodontics company that provides superior dental outcomes with a dual specialty integrated care model.
Cavapharma is a Kirkland, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Envisia Therapeutics, formed by Liquidia Technologies in 2013, is a privately held biotechnology company focused on the development of novel ocular therapies. Envisia is leveraging the unique and powerful properties of the PRINT® platform to develop therapies for a variety of ocular conditions, the most advanced of which is ENV515, for the treatment of glaucoma. ENV515 is a novel extended-release formulation of a prostaglandin analogue formulation. It has the potential to significantly limit disease progression and vision loss through improved product performance and patient compliance. Envisia is located in Research Triangle Park, North Carolina.
PresenceLearning is the leading provider of online special education services for early intervention and K-12 students in the United States. We provide “anytime, anywhere” access to a network of more than 700 fully licensed, highly qualified clinicians who work face-to-face with students via live videoconferencing using our proprietary platform and instructional activities. Since our founding in 2009, we have delivered more than 1,000,000 sessions of teletherapy to hundreds of school districts, charter schools, and virtual school organizations across the United States. And we`re not stopping there. The shortage of Speech-Language Pathologists (SLPs), Occupational Therapists (OTs), and Mental Health Professionals (MHPs) is reaching crisis proportions, innovative modes of delivery have become essential for providing access to therapeutic services. Our dedicated team of employees is committed to seeing children thrive via the growing online therapy revolution.